Primary completion date changed
Before: 1 Dec 2027. After: 21 Jan 2027.
Study sponsor: TG Therapeutics, Inc. · TGTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: 1 Dec 2027. After: 21 Jan 2027.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab. After: Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab.
Before: 1 Sep 2026. After: 1 Dec 2027.
Before: 600 participants (planned). After: 800 participants (planned).
Before: 1 Mar 2026. After: 1 Sep 2026.